Labcorp Finalizes Strategic Relationship with Jefferson Health

Rhea-AI Summary

Labcorp has completed a transaction to establish a strategic relationship with Jefferson Health, the largest health system serving the greater Philadelphia and Southern New Jersey region. This collaboration aims to improve healthcare access, standardize laboratory testing, and enhance academic capabilities. Labcorp and Jefferson will also establish the IDEA initiative to foster innovation in testing capabilities and technologies.

BURLINGTON, N.C., July 13, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia and Southern New Jersey region.

"This groundbreaking agreement between Jefferson and Labcorp will better serve providers and patients throughout the greater Philadelphia and southern New Jersey region by increasing access, breadth of testing and affordability, as well as enriching the academic prowess and reach of Jefferson Health," said Bill Haas, senior vice president of Labcorp's Northeast Division. "This transaction further demonstrates our commitment to advancing our laboratory services model with leading academic health systems, and we are looking forward to building upon Jefferson's longstanding track record of delivering comprehensive diagnostic care to its patients."

Through this collaboration, the scope and productivity of Jefferson's current offerings will expand, and healthcare access will be improved for underserved communities in Philadelphia and the surrounding areas. This new relationship will also help standardize laboratory testing across the entire health system, creating consistency and optimizing patient care and safety at all locations. Leveraging Jefferson's pathology and laboratory expertise, the Jefferson laboratory will continue to provide services for all inpatients and outpatients along with select specialty testing, including anatomic pathology, genomics and molecular virology. Additionally, Labcorp and Jefferson will work together to establish the Innovation Driving Excellence in Academics (IDEA) initiative, which will foster innovation and advance testing capabilities and technologies to improve health outcomes.

"By combining Jefferson's history of outstanding, leading-edge service with Labcorp's comprehensive capabilities and resources, we are confident these offerings will make it easier for both physicians and patients to seamlessly receive high-quality, timely laboratory services in the most cost effective and efficient manner," said Mark Whalen, executive vice president and chief strategy and administrative officer of Jefferson. "In addition, this relationship will enable us to further our academic mission by expanding residency and fellowship training opportunities in the areas of pathology and laboratory medicine."

This relationship follows other strategic collaborations that Labcorp has established with a range of local and regional health systems to enhance laboratory services for patients and providers.

The definitive agreements for the transaction were announced on May 3, 2023.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

About Jefferson
Nationally ranked, Jefferson, which is principally located in the greater Philadelphia region and southern New Jersey, is reimagining health care and higher education to create unparalleled value. Jefferson is more than 42,000 people strong, dedicated to providing the highest-quality, compassionate clinical care for patients; making our communities healthier and stronger; preparing tomorrow's professional leaders for 21st-century careers; and creating new knowledge through basic/programmatic, clinical and applied research. Thomas Jefferson University, home of Sidney Kimmel Medical College and the Kanbar College of Design, Engineering and Commerce, dates back to 1824 and today comprises 10 colleges and three schools offering 200 undergraduate and graduate programs to more than 8,400 students. Jefferson Health, nationally ranked as one of the top health care systems in the country and the largest provider in the Philadelphia area, serves patients through millions of encounters each year at 17 hospitals (10 are Magnet® designated by the ANCC for nursing excellence) and over 50 outpatient and urgent care locations throughout the region. Health Partners Plans is a not-for-profit managed health care organization providing a broad range of health coverage options in Pennsylvania and New Jersey for more than 35 years.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to the completion of the acquisition of the outreach laboratory business of Jefferson Health, the strategic laboratory relationship between the parties, and the anticipated benefits of the transaction for providers and patients. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-finalizes-strategic-relationship-with-jefferson-health-301876598.html

SOURCE Labcorp

FAQ

What is the strategic relationship announced by Labcorp?

Labcorp has established a strategic relationship with Jefferson Health, the largest health system serving the greater Philadelphia and Southern New Jersey region.

What are the goals of the collaboration between Labcorp and Jefferson Health?

The collaboration aims to increase access, breadth of testing, and affordability for providers and patients in the region. It also seeks to standardize laboratory testing, optimize patient care and safety, and enhance academic capabilities.

What is the IDEA initiative mentioned in the press release?

The IDEA initiative is a collaboration between Labcorp and Jefferson Health to foster innovation and advance testing capabilities and technologies in order to improve health outcomes.

When were the definitive agreements for the transaction announced?

The definitive agreements for the transaction were announced on May 3, 2023.